Medical School MD-PhD Program

Research products

All my research products

Selected research products

Schwartz S, Szeto C, Tian Y, Cecchi F, Corallo S, Calegari MA, Di Bartolomeo M, Morano F, Raimondi A, Fuca G, Martinetti A, De Pascalis I, Martini M, Belfiore A, Milione M, Orlandi A, Barault L, Barone C, de Braud F, Di Nicolantonio F, Benz S, Hembrough T, Pietrantonio F. (2019) Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase. European journal of cancer (Oxford, England : 1990) 107 164-174 [DOI  PMID]

Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, Mussolin B, Falcomata C, Binder AM, Cristiano C, Oddo D, Guarrera S, Cancelliere C, Bustreo S, Bencardino K, Maden S, Vanzati A, Zavattari P, Matullo G, Truini M, Grady WM, Racca P, Michels KB, Siena S, Esteller M, Bardelli A, Sartore-Bianchi A, Di Nicolantonio F. (2018) Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. Gut 67(11) 1995-2005 [DOI  PMID]

Siravegna G, Lazzari L, Crisafulli G, Sartore-Bianchi A, Mussolin B, Cassingena A, Martino C, Lanman RB, Nagy RJ, Fairclough S, Rospo G, Corti G, Bartolini A, Arcella P, Montone M, Lodi F, Lorenzato A, Vanzati A, Valtorta E, Cappello G, Bertotti A, Lonardi S, Zagonel V, Leone F, Russo M, Balsamo A, Truini M, Di Nicolantonio F, Amatu A, Bonazzina E, Ghezzi S, Regge D, Vanzulli A, Trusolino L, Siena S, Marsoni S, Bardelli A. (2018) Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer. Cancer cell 34(1) 148-162.e7 [DOI  PMID]

Rizzolio S, Cagnoni G, Battistini C, Bonelli S, Isella C, Van Ginderachter JA, Bernards R, Di Nicolantonio F, Giordano S, Tamagnone L. (2018) Neuropilin-1 upregulation elicits adaptive resistance to oncogene-targeted therapies. The Journal of clinical investigation 128(9) 3976-3990 [DOI  PMID]

Russo M, Lamba S, Lorenzato A, Sogari A, Corti G, Rospo G, Mussolin B, Montone M, Lazzari L, Arena S, Oddo D, Linnebacher M, Sartore-Bianchi A, Pietrantonio F, Siena S, Di Nicolantonio F, Bardelli A. (2018) Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies. Nature communications 9(1) 2287 [DOI  PMID]

Morano F, Corallo S, Niger M, Barault L, Milione M, Berenato R, Moretto R, Randon G, Antista M, Belfiore A, Raimondi A, Nichetti F, Martinetti A, Battaglia L, Perrone F, Pruneri G, Falcone A, Di Bartolomeo M, de Braud F, Di Nicolantonio F, Cremolini C, Pietrantonio F. (2018) Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. Annals of oncology : official journal of the European Society for Medical Oncology 29(8) 1800-1806 [DOI  PMID]

Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M. (2018) Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer. Oncotarget 9(17) 13834-13847 [DOI  PMID]

Fadda A, Gentilini D, Moi L, Barault L, Leoni VP, Sulas P, Zorcolo L, Restivo A, Cabras F, Fortunato F, Zavattari C, Varesco L, Gismondi V, De Miglio MR, Scanu AM, Colombi F, Lombardi P, Sarotto I, Loi E, Leone F, Giordano S, Di Nicolantonio F, Columbano A, Zavattari P. (2018) Colorectal cancer early methylation alterations affect the crosstalk between cell and surrounding environment, tracing a biomarker signature specific for this tumor. International journal of cancer 143(4) 907-920 [DOI  PMID]

Pietrantonio F, Di Nicolantonio F, Schrock AB, Lee J, Morano F, Fuca G, Nikolinakos P, Drilon A, Hechtman JF, Christiansen J, Gowen K, Frampton GM, Gasparini P, Rossini D, Gigliotti C, Kim ST, Prisciandaro M, Hodgson J, Zaniboni A, Chiu VK, Milione M, Patel R, Miller V, Bardelli A, Novara L, Wang L, Pupa SM, Sozzi G, Ross J, Di Bartolomeo M, Bertotti A, Ali S, Trusolino L, Falcone A, de Braud F, Cremolini C. (2018) RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Annals of oncology : official journal of the European Society for Medical Oncology 29(6) 1394-1401 [DOI  PMID]

Riganti C, Lingua MF, Salaroglio IC, Falcomata C, Righi L, Morena D, Picca F, Oddo D, Kopecka J, Pradotto M, Libener R, Orecchia S, Bironzo P, Comunanza V, Bussolino F, Novello S, Scagliotti GV, Di Nicolantonio F*, Taulli R. (2018) Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. Oncoimmunology 7(3) e1398874 [DOI  PMID] *corresponding author

Pietrantonio F, Di Nicolantonio F*, Schrock AB, Lee J, Tejpar S, Sartore-Bianchi A, Hechtman JF, Christiansen J, Novara L, Tebbutt N, Fuca G, Antoniotti C, Kim ST, Murphy D, Berenato R, Morano F, Sun J, Min B, Stephens PJ, Chen M, Lazzari L, Miller VA, Shoemaker R, Amatu A, Milione M, Ross JS, Siena S, Bardelli A, Ali SM, Falcone A, de Braud F, Cremolini C. (2017) ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer. Journal of the National Cancer Institute 109(12) [DOI  PMID] *corresponding author

Germano G, Mauri G, Siravegna G, Dive C, Pierce J, Di Nicolantonio F, D'Incalci M, Bardelli A, Siena S, Sartore-Bianchi A. (2018) Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer. Clinical colorectal cancer 17(1) 80-83 [DOI  PMID]

Germano G, Lamba S, Rospo G, Barault L, Magri A, Maione F, Russo M, Crisafulli G, Bartolini A, Lerda G, Siravegna G, Mussolin B, Frapolli R, Montone M, Morano F, de Braud F, Amirouchene-Angelozzi N, Marsoni S, D'Incalci M, Orlandi A, Giraudo E, Sartore-Bianchi A, Siena S, Pietrantonio F, Di Nicolantonio F, Bardelli A. (2017) Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552(7683) 116-120 [DOI  PMID]

Carbone C, Piro G, Gaianigo N, Ligorio F, Santoro R, Merz V, Simionato F, Zecchetto C, Falco G, Conti G, Kamga PT, Krampera M, Di Nicolantonio F, De Franceschi L, Scarpa A, Tortora G, Melisi D. (2018) Adipocytes sustain pancreatic cancer progression through a non-canonical WNT paracrine network inducing ROR2 nuclear shuttling. International journal of obesity (2005) 42(3) 334-343 [DOI  PMID]

Oddo D, Siravegna G, Gloghini A, Vernieri C, Mussolin B, Morano F, Crisafulli G, Berenato R, Corti G, Volpi CC, Buscarino M, Niger M, Dunne PD, Rospo G, Valtorta E, Bartolini A, Fuca G, Lamba S, Martinetti A, Di Bartolomeo M, de Braud F, Bardelli A, Pietrantonio F, Di Nicolantonio F. (2017) Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. British journal of cancer 117(3) 347-352 [DOI  PMID]

Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di Nicolantonio F, Siena S, Bardelli A. (2017) Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology 28(6) 1302-1308 [DOI  PMID]

Carbone C, Piro G, Simionato F, Ligorio F, Cremolini C, Loupakis F, Ali G, Rossini D, Merz V, Santoro R, Zecchetto C, Zanotto M, Di Nicolantonio F, Bardelli A, Fontanini G, Tortora G, Melisi D. (2017) Homeobox B9 Mediates Resistance to Anti-VEGF Therapy in Colorectal Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 23(15) 4312-4322 [DOI  PMID]

Fujii T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Huang HJ, Veronese S, Di Nicolantonio F, Pingle S, Vibat CRT, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz ES, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. (2017) Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 23(14) 3657-3666 [DOI  PMID]

Sartore-Bianchi A, Pietrantonio F, Amatu A, Milione M, Cassingena A, Ghezzi S, Caporale M, Berenato R, Falcomata C, Pellegrinelli A, Bardelli A, Nichelatti M, Tosi F, De Braud F, Di Nicolantonio F, Barault L, Siena S. (2017) Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients. European journal of cancer (Oxford, England : 1990) 71 43-50 [DOI  PMID]

Comunanza V, Cora D, Orso F, Consonni FM, Middonti E, Di Nicolantonio F, Buzdin A, Sica A, Medico E, Sangiolo D, Taverna D, Bussolino F. (2017) VEGF blockade enhances the antitumor effect of BRAFV600E inhibition. EMBO molecular medicine 9(2) 219-237 [DOI  PMID]

Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. (2016) Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nature communications 7 13665 [DOI  PMID]

Picco G, Petti C, Sassi F, Grillone K, Migliardi G, Rossi T, Isella C, Di Nicolantonio F, Sarotto I, Sapino A, Bardelli A, Trusolino L, Bertotti A, Medico E. (2017) Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer. Journal of the National Cancer Institute 109(2) [DOI  PMID]

Pietrantonio F, Oddo D, Gloghini A, Valtorta E, Berenato R, Barault L, Caporale M, Busico A, Morano F, Gualeni AV, Alessi A, Siravegna G, Perrone F, Di Bartolomeo M, Bardelli A, de Braud F, Di Nicolantonio F. (2016) MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer. Cancer discovery 6(9) 963-71 [DOI  PMID]

Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. (2016) Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer. Cancer research 76(15) 4504-15 [DOI  PMID]

Piro G, Carbone C, Cataldo I, Di Nicolantonio F, Giacopuzzi S, Aprile G, Simionato F, Boschi F, Zanotto M, Mina MM, Santoro R, Merz V, Sbarbati A, de Manzoni G, Scarpa A, Tortora G, Melisi D. (2016) An FGFR3 Autocrine Loop Sustains Acquired Resistance to Trastuzumab in Gastric Cancer Patients. Clinical cancer research : an official journal of the American Association for Cancer Research 22(24) 6164-6175 [DOI  PMID]

Bartolini A, Cardaci S, Lamba S, Oddo D, Marchio C, Cassoni P, Amoreo CA, Corti G, Testori A, Bussolino F, Pasqualini R, Arap W, Cora D, Di Nicolantonio F*, Marchio S. (2016) BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS-Mutant Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 22(19) 4923-4933 [DOI  PMID] *corresponding author

Vecchione L, Gambino V, Raaijmakers J, Schlicker A, Fumagalli A, Russo M, Villanueva A, Beerling E, Bartolini A, Mollevi DG, El-Murr N, Chiron M, Calvet L, Nicolazzi C, Combeau C, Henry C, Simon IM, Tian S, in 't Veld S, D'ario G, Mainardi S, Beijersbergen RL, Lieftink C, Linn S, Rumpf-Kienzl C, Delorenzi M, Wessels L, Salazar R, Di Nicolantonio F, Bardelli A, van Rheenen J, Medema RH, Tejpar S, Bernards R. (2016) A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. Cell 165(2) 317-30 [DOI  PMID]

Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S. (2016) Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 27(6) 1062-7 [DOI  PMID]

Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. (2016) MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Science translational medicine 8(324) 324ra14 [DOI  PMID]

Righi L, Vatrano S, Di Nicolantonio F, Massa F, Rossi G, Cavazza A, Volante M, Votta A, Izzo S, Lo Iacono M, Ardissone F, Di Maio M, Novello S, Scagliotti GV, Papotti M. (2016) Retrospective Multicenter Study Investigating the Role of Targeted Next-Generation Sequencing of Selected Cancer Genes in Mucinous Adenocarcinoma of the Lung. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 11(4) 504-15 [DOI  PMID]

Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, Mussolin B, Kwak EL, Buscarino M, Lazzari L, Valtorta E, Truini M, Jessop NA, Robinson HE, Hong TS, Mino-Kenudson M, Di Nicolantonio F, Thabet A, Sartore-Bianchi A, Siena S, Iafrate AJ, Bardelli A, Corcoran RB. (2016) Tumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer. Cancer discovery 6(2) 147-153 [DOI  PMID]

Russo M, Misale S, Wei G, Siravegna G, Crisafulli G, Lazzari L, Corti G, Rospo G, Novara L, Mussolin B, Bartolini A, Cam N, Patel R, Yan S, Shoemaker R, Wild R, Di Nicolantonio F, Bianchi AS, Li G, Siena S, Bardelli A. (2016) Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer. Cancer discovery 6(1) 36-44 [DOI  PMID]

Misale S, Bozic I, Tong J, Peraza-Penton A, Lallo A, Baldi F, Lin KH, Truini M, Trusolino L, Bertotti A, Di Nicolantonio F, Nowak MA, Zhang L, Wood KC, Bardelli A. (2015) Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nature communications 6 8305 [DOI  PMID]

Prahallad A, Heynen GJ, Germano G, Willems SM, Evers B, Vecchione L, Gambino V, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Bernards R. (2015) PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs. Cell reports 12(12) 1978-85 [DOI  PMID]

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature medicine 21(7) 827 [DOI  PMID]

Barault L, Amatu A, Bleeker FE, Moutinho C, Falcomata C, Fiano V, Cassingena A, Siravegna G, Milione M, Cassoni P, De Braud F, Ruda R, Soffietti R, Venesio T, Bardelli A, Wesseling P, de Witt Hamer P, Pietrantonio F, Siena S, Esteller M, Sartore-Bianchi A, Di Nicolantonio F. (2015) Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Annals of oncology : official journal of the European Society for Medical Oncology 26(9) 1994-9 [DOI  PMID]

Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu A, Lauricella C, Lamba S, Hobor S, Avallone A, Valtorta E, Rospo G, Medico E, Motta V, Antoniotti C, Tatangelo F, Bellosillo B, Veronese S, Budillon A, Montagut C, Racca P, Marsoni S, Falcone A, Corcoran RB, Di Nicolantonio F, Loupakis F, Siena S, Sartore-Bianchi A, Bardelli A. (2015) Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nature medicine 21(7) 795-801 [DOI  PMID]

Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, Buscarino M, Isella C, Lamba S, Martinoglio B, Veronese S, Siena S, Sartore-Bianchi A, Beccuti M, Mottolese M, Linnebacher M, Cordero F, Di Nicolantonio F*, Bardelli A. (2015) The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nature communications 6 7002 [DOI  PMID] *corresponding author

Maione F, Oliaro-Bosso S, Meda C, Di Nicolantonio F, Bussolino F, Balliano G, Viola F, Giraudo E. (2015) The cholesterol biosynthesis enzyme oxidosqualene cyclase is a new target to impair tumour angiogenesis and metastasis dissemination. Scientific reports 5 9054 [DOI  PMID]

Arena S, Bellosillo B, Siravegna G, Martinez A, Canadas I, Lazzari L, Ferruz N, Russo M, Misale S, Gonzalez I, Iglesias M, Gavilan E, Corti G, Hobor S, Crisafulli G, Salido M, Sanchez J, Dalmases A, Bellmunt J, De Fabritiis G, Rovira A, Di Nicolantonio F, Albanell J, Bardelli A, Montagut C. (2015) Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 21(9) 2157-66 [DOI  PMID]

Alamo P, Gallardo A, Di Nicolantonio F, Pavon MA, Casanova I, Trias M, Mangues MA, Lopez-Pousa A, Villaverde A, Vazquez E, Bardelli A, Cespedes MV, Mangues R. (2015) Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 29(2) 464-76 [DOI  PMID]

Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. (2014) Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer discovery 4(11) 1269-80 [DOI  PMID]

Lamba S, Russo M, Sun C, Lazzari L, Cancelliere C, Grernrum W, Lieftink C, Bernards R, Di Nicolantonio F*, Bardelli A. (2014) RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. Cell reports 8(5) 1475-83 [DOI  PMID] *corresponding author

Hobor S, Van Emburgh BO, Crowley E, Misale S, Di Nicolantonio F, Bardelli A. (2014) TGFalpha and amphiregulin paracrine network promotes resistance to EGFR blockade in colorectal cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research 20(24) 6429-38 [DOI  PMID]

Van Emburgh BO, Sartore-Bianchi A, Di Nicolantonio F, Siena S, Bardelli A. (2014) Acquired resistance to EGFR-targeted therapies in colorectal cancer. Molecular oncology 8(6) 1084-94 [DOI  PMID]

Sun C, Hobor S, Bertotti A, Zecchin D, Huang S, Galimi F, Cottino F, Prahallad A, Grernrum W, Tzani A, Schlicker A, Wessels LF, Smit EF, Thunnissen E, Halonen P, Lieftink C, Beijersbergen RL, Di Nicolantonio F, Bardelli A, Trusolino L, Bernards R. (2014) Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3. Cell reports 7(1) 86-93 [DOI  PMID]

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R. (2014) Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature 508(7494) 118-22 [DOI  PMID]

Misale S, Arena S, Lamba S, Siravegna G, Lallo A, Hobor S, Russo M, Buscarino M, Lazzari L, Sartore-Bianchi A, Bencardino K, Amatu A, Lauricella C, Valtorta E, Siena S, Di Nicolantonio F, Bardelli A. (2014) Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Science translational medicine 6(224) 224ra26 [DOI  PMID]

Russo M, Di Nicolantonio F, Bardelli A. (2014) Climbing RAS, the everest of oncogenes. Cancer discovery 4(1) 19-21 [DOI  PMID]

Crowley EH, Arena S, Lamba S, Di Nicolantonio F, Bardelli A. (2014) Targeted knock-in of the polymorphism rs61764370 does not affect KRAS expression but reduces let-7 levels. Human mutation 35(2) 208-14 [DOI  PMID]

Zecchin D, Boscaro V, Medico E, Barault L, Martini M, Arena S, Cancelliere C, Bartolini A, Crowley EH, Bardelli A, Gallicchio M, Di Nicolantonio F. (2013) BRAF V600E is a determinant of sensitivity to proteasome inhibitors. Molecular cancer therapeutics 12(12) 2950-61 [DOI  PMID]

Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. (2013) Liquid biopsy: monitoring cancer-genetics in the blood. Nature reviews. Clinical oncology 10(8) 472-84 [DOI  PMID]

Bardelli A, Corso S, Bertotti A, Hobor S, Valtorta E, Siravegna G, Sartore-Bianchi A, Scala E, Cassingena A, Zecchin D, Apicella M, Migliardi G, Galimi F, Lauricella C, Zanon C, Perera T, Veronese S, Corti G, Amatu A, Gambacorta M, Diaz LA Jr, Sausen M, Velculescu VE, Comoglio P, Trusolino L, Di Nicolantonio F, Giordano S, Siena S. (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer discovery 3(6) 658-73 [DOI  PMID]

Michieli P, Di Nicolantonio F. (2013) Targeted therapies: Tivantinib--a cytotoxic drug in MET inhibitor's clothes? Nature reviews. Clinical oncology 10(7) 372-4 [DOI  PMID]

Di Nicolantonio F, Bardelli A. (2013) Mouse models of Kras-mutant colorectal cancer: valuable GEMMs for drug testing? Clinical cancer research : an official journal of the American Association for Cancer Research 19(11) 2794-6 [DOI  PMID]

Valtorta E, Misale S, Sartore-Bianchi A, Nagtegaal ID, Paraf F, Lauricella C, Dimartino V, Hobor S, Jacobs B, Ercolani C, Lamba S, Scala E, Veronese S, Laurent-Puig P, Siena S, Tejpar S, Mottolese M, Punt CJ, Gambacorta M, Bardelli A, Di Nicolantonio F. (2013) KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. International journal of cancer 133(5) 1259-65 [DOI  PMID]

Zecchin D, Arena S, Martini M, Sassi F, Pisacane A, Di Nicolantonio F, Bardelli A. (2013) Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. Human mutation 34(2) 330-7 [DOI  PMID]

Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A. (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404) 532-6 [DOI  PMID]

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Cora D, Di Nicolantonio F, Buscarino M, Petti C, Ribero D, Russolillo N, Muratore A, Massucco P, Pisacane A, Molinaro L, Valtorta E, Sartore-Bianchi A, Risio M, Capussotti L, Gambacorta M, Siena S, Medico E, Sapino A, Marsoni S, Comoglio PM, Bardelli A, Trusolino L. (2011) A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer discovery 1(6) 508-23 [DOI  PMID]

Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A. (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clinical cancer research : an official journal of the American Association for Cancer Research 18(9) 2515-25 [DOI  PMID]

Prahallad A, Sun C, Huang S, Di Nicolantonio F**, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387) 100-3 [DOI  PMID] **co-first author

Bottos A, Martini M, Di Nicolantonio F, Comunanza V, Maione F, Minassi A, Appendino G, Bussolino F, Bardelli A. (2012) Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proceedings of the National Academy of Sciences of the United States of America 109(6) E353-9 [DOI  PMID]

Rosa R, Melisi D, Damiano V, Bianco R, Garofalo S, Gelardi T, Agrawal S, Di Nicolantonio F, Scarpa A, Bardelli A, Tortora G. (2011) Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research 17(20) 6531-41 [DOI  PMID]

Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M. (2011) Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 17(14) 4901-14 [DOI  PMID]

Zecchin D, Di Nicolantonio F. (2011) Transfection and DNA-mediated gene transfer. Methods in molecular biology (Clifton, N.J.) 731 435-50 [DOI  PMID]

Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Funaioli C, Cipani T, Amatu A, Pietrogiovanna L, Schiavo R, Di Nicolantonio F, Artale S, Bardelli A, Siena S. (2010) Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer. Cancer treatment reviews 36 Suppl 3 S1-5 [DOI  PMID]

De Roock W, Jonker DJ, Di Nicolantonio F**, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. (2010) Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16) 1812-20 [DOI  PMID] **co-first author

Di Nicolantonio F, Arena S, Tabernero J, Grosso S, Molinari F, Macarulla T, Russo M, Cancelliere C, Zecchin D, Mazzucchelli L, Sasazuki T, Shirasawa S, Geuna M, Frattini M, Baselga J, Gallicchio M, Biffo S, Bardelli A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. The Journal of clinical investigation 120(8) 2858-66 [DOI  PMID]

Sartore-Bianchi A, Bencardino K, Di Nicolantonio F, Pozzi F, Funaioli C, Gambi V, Arena S, Martini M, Lamba S, Cassingena A, Schiavo R, Bardelli A, Siena S. (2010) Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer. Targeted oncology 5(1) 19-28 [DOI  PMID]

Di Nicolantonio F, Arena S, Gallicchio M, Bardelli A. (2010) Isogenic mutant human cells: a new tool for personalized cancer medicine. Cell cycle (Georgetown, Tex.) 9(1) 20-1 [DOI  PMID]

Sartore-Bianchi A, Di Nicolantonio F**, Nichelatti M, Molinari F, De Dosso S, Saletti P, Martini M, Cipani T, Marrapese G, Mazzucchelli L, Lamba S, Veronese S, Frattini M, Bardelli A, Siena S. (2009) Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer. PloS one 4(10) e7287 [DOI  PMID] **co-first author

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. (2009) Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. Journal of the National Cancer Institute 101(19) 1308-24 [DOI  PMID]

Palmioli A, Sacco E, Airoldi C, Di Nicolantonio F, D'Urzo A, Shirasawa S, Sasazuki T, Di Domizio A, De Gioia L, Martegani E, Bardelli A, Peri F, Vanoni M. (2009) Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D). Biochemical and biophysical research communications 386(4) 593-7 [DOI  PMID]

Sartore-Bianchi A, Martini M, Molinari F, Veronese S, Nichelatti M, Artale S, Di Nicolantonio F, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer research 69(5) 1851-7 [DOI  PMID]

Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, Fantozzi R, Medico E, Bardelli A. (2008) Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences of the United States of America 105(52) 20864-9 [DOI  PMID]

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 26(35) 5705-12 [DOI  PMID]

Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. (2007) Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer research 67(6) 2643-8 [DOI  PMID]

Fernando A, Glaysher S, Conroy M, Pekalski M, Smith J, Knight LA, Di Nicolantonio F, Cree IA. (2006) Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines. Anti-cancer drugs 17(8) 913-9 [DOI  PMID]

Knight LA, Di Nicolantonio F, Whitehouse PA, Mercer SJ, Sharma S, Glaysher S, Hungerford JL, Hurren J, Lamont A, Cree IA. (2006) The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anti-cancer drugs 17(6) 649-55 [DOI  PMID]

Bhandari P, Bateman AC, Mehta RL, Stacey BS, Johnson P, Cree IA, Di Nicolantonio F, Patel P. (2006) Prognostic significance of cyclooxygenase-2 (COX-2) expression in patients with surgically resectable adenocarcinoma of the oesophagus. BMC cancer 6 134 [DOI  PMID]

Di Nicolantonio F, Bardelli A. (2006) Kinase mutations in cancer: chinks in the enemy's armour? Current opinion in oncology 18(1) 69-76 [PMID]

Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Glaysher S, Di Palma S, Johnson P, Somers SS, Toh S, Higgins B, Lamont A, Gulliford T, Hurren J, Yiangou C, Cree IA. (2005) Cancer cell adaptation to chemotherapy. BMC cancer 5 78 [DOI  PMID]

Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. The Lancet. Oncology 6(5) 279-86 [DOI  PMID]

Mercer SJ, Di Nicolantonio F**, Knight LA, Gabriel FG, Whitehouse PA, Sharma S, Fernando A, Bhandari P, Somers SS, Toh SK, Cree IA. (2005) Rapid up-regulation of cyclooxygenase-2 by 5-fluorouracil in human solid tumors. Anti-cancer drugs 16(5) 495-500 [PMID] **co-first author

Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Sharma S, Charlton PA, Norris D, Cree IA. (2004) The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples. Molecular cancer therapeutics 3(12) 1631-7 [PMID]

Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA. (2004) The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer 4 83 [DOI  PMID]

Di Nicolantonio F, Knight LA, Glaysher S, Whitehouse PA, Mercer SJ, Sharma S, Mills L, Prin A, Johnson P, Charlton PA, Norris D, Cree IA. (2004) Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anti-cancer drugs 15(9) 861-9 [PMID]

Di Nicolantonio F, Knight LA, Di Palma S, Sharma S, Whitehouse PA, Mercer SJ, Charlton PA, Norris D, Cree IA. (2004) Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors. Anti-cancer drugs 15(9) 849-60 [PMID]

Whitehouse PA, Mercer SJ, Knight LA, Di Nicolantonio F, O'Callaghan A, Cree IA. (2003) Combination chemotherapy in advanced gastrointestinal cancers: ex vivo sensitivity to gemcitabine and mitomycin C. British journal of cancer 89(12) 2299-304 [DOI  PMID]

Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Di Nicolantonio F, Glaysher S, Toh S, Cree IA. (2003) Heterogeneity of chemosensitivity of esophageal and gastric carcinoma. Anti-cancer drugs 14(6) 397-403 [DOI  PMID]

Sharma S, Neale MH, Di Nicolantonio F, Knight LA, Whitehouse PA, Mercer SJ, Higgins BR, Lamont A, Osborne R, Hindley AC, Kurbacher CM, Cree IA. (2003) Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC cancer 3 19 [DOI  PMID]

Whitehouse PA, Knight LA, Di Nicolantonio F, Mercer SJ, Sharma S, Cree IA. (2003) Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA). Anti-cancer drugs 14(5) 369-75 [DOI  PMID]

Edmunds SC, Cree IA, Di Nicolantonio F, Hungerford JL, Hurren JS, Kelsell DP. (2003) Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. British journal of cancer 88(9) 1403-5 [DOI  PMID]

Schondorf T, Neumann R, Benz C, Becker M, Riffelmann M, Gohring UJ, Sartorius J, von Konig CH, Breidenbach M, Valter MM, Hoopmann M, Di Nicolantonio F, Kurbacher CM. (2003) Cisplatin, doxorubicin and paclitaxel induce mdr1 gene transcription in ovarian cancer cell lines. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 161 111-6 [PMID]

Di Nicolantonio F, Neale M, Onadim Z, Hungerford JL, Kingston JL, Cree IA. (2003) The chemosensitivity profile of retinoblastoma. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 161 73-80 [PMID]

Di Nicolantonio F, Neale MH, Knight LA, Lamont A, Skailes GE, Osborne RJ, Allerton R, Kurbacher CM, Cree IA. (2002) Use of an ATP-based chemosensitivity assay to design new combinations of high-concentration doxorubicin with other drugs for recurrent ovarian cancer. Anti-cancer drugs 13(6) 625-30 [PMID]

Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. (2002) Chemosensitization of solid tumor cells by alteration of their susceptibility to apoptosis. Current opinion in investigational drugs (London, England : 2000) 3(4) 641-7 [PMID]

Cree IA, Knight L, Di Nicolantonio F, Sharma S, Gulliford T. (2002) Chemosensitization of solid tumors by modulation of resistance mechanisms. Current opinion in investigational drugs (London, England : 2000) 3(4) 634-40 [PMID]

Cantoni L, Di Nicolantonio F, Barelli D, Rizzardini M, De Matteis F. (2001) Modulation of cerebellar and hepatic nitric oxide synthase by exogenous arginine and endotoxin. Nitric oxide : biology and chemistry 5(2) 198-207 [DOI  PMID]

Courses

• Biochimica (SCB0036D)
  Laurea in Tecnica della Riabilitazione Psichiatrica
• Biochimica (Canale D) (SME0980)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Biochimica d'organo (canale D) (SME0980C)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Biochimica metabolica (canale D) (SME0980B)
  Laurea Magistrale in Medicina e Chirurgia - sede di Torino
• Epigenetica applicata alla diagnosi e terapia della patologie neoplastiche. Responsabile prof Federica Dinicolantonio
  Programma MD-PhD della Scuola di Medicina
• Scienze propedeutiche e biomediche (SCB0036)
  Laurea in Tecnica della Riabilitazione Psichiatrica
• TIROCINIO di BIOLOGIA MOLECOLARE CLINICA (SME0870)
  Corso di Laurea Magistrale in Biotecnologie Mediche - Classe LM-9

Research topics

Changes in DNA methylation in response to environmental stimuli may be associated with an increase in the risk of neoplastic transformation.  Changes in epigenetic regulatory events are also key to maintaining the tumorigenic phenotype. The laboratory of Cancer Epigenetics investigates epigenetic biomarkers for personalized cancer detection and therapy.

 

Recent accomplishments:

• Methylation changes are considered an early event in colorectal carcinogenesis. For this reason, DNA methylation markers have been proposed for early CRC detection using stool or blood samples. We have recently identified a panel of loci that are differentially hypermethylated in colorectal cancer patient plasma samples compared to self-declared healthy individuals (Barault L et al., 2018 Nov;67(11):1995-2005. pii: gutjnl-2016-313372).
• In order to deliver precision oncology for advanced colorectal cancer patients, we have validated MGMT hypermethylation in solid and liquid biopsies as a predictive marker of response to alkylating agent based therapy (Barault L et al., Ann Oncol. 2015; 26:1994-9); Amatu A, Barault L et al., Ann Oncol. 2016;27:1062-7).
• Identifying the molecular bases of response or resistance to first-line anti-cancer treatments may aid in designing and testing sequences of drugs rationally designed on the modifications induced by the first agent on the tumor molecular landscape. In this regard, we have unveiled the role of receptor tyrosine kinase signaling or MAPK pathyway molecular alterations as biomarkers of acquired resistance to BRAF combination therapies in BRAF mutant colorectal patients and have shown how this knowledge can help designing further salvage treatment lines (Oddo D et al., Cancer Res. 2016;7 6:4504-15; Pietrantonio F et al., Cancer Discov. 2016; 6:963-71; Oddo D et al., Br J Cancer. 2017;117:347-352).  

 

Current and future research interests include:

• assessing methylation in liquid biopsy as a marker of minimal residual disease in patients who have undergone primary colonic tumor resection;
• assessing molecular markers of response/relapse to temozolomide-based chemotherapy in advanced colorectal cancer patients, including the impact of temozolomide on the tumor molecular landscape;
• redefining the epigenetic landscape of BRAF mutant colorectal cancer for prognostic and predictive stratification;
• investigating the impact of metabolic and tumor microenvironment changes on enzymes involved in DNA methylation and their role in modulating anticancer drug response.

 

Activities in agenda

See my calendar

Academic bodies

• Department Council - Department of Oncology
• Departmental Board

• Consiglio di Dipartimento - Dipartimento di Oncologia
• Giunta del Dipartimento di Oncologia

• Collegio Docenti

Office hours

Su appuntamento da richiedere via e-mail.